WHO Drug Information Vol. 31, No.

4, 2017

ATC/DDD classification
The Anatomical Therapeutic Chemical (ATC) classification system and the
Defined Daily Dose (DDD) as a measuring unit are tools for exchanging and
comparing data on drug use at international, national or local levels. The ATC/
DDD system has become the gold standard for international drug utilization
research. It is maintained by the WHO Collaborating Centre for Drug Statistics
Methodology in Oslo, Norway. Visit www.whocc.no/ for more information.

ATC/DDD classification (temporary)

The following ATC codes and DDDs were agreed at the meeting of the WHO
International Working Group for Drug Statistics Methodology in October 2017.
Comments or objections to the decisions from the meeting should be forwarded to
the WHO Collaborating Centre for Drug Statistics Methodology before 1 February
2018. If no objections are received before this date, the new ATC codes and DDDs
will be considered final and included in the January 2019 version of the ATC/DDD
Index.

New ATC 5th level codes

ATC level name/INN ATC code
ambrisentan and tadalafil C02KX52
atazanavir and ritonavir J05AR23
atezolizumab L01XC32
avelumab L01XC31
caplacizumab B01AX07
cefteram J01DD18
cladribine1 L04AA40
clenbuterol and ambroxol R03CC63
crisaborole D11AH06
crofelemer A07XA06
cytarabine and daunorubicin L01XY01
dacomitinib L01XE47
dapivirine G01AX17
delafloxacin J01MA23
doxepin D04AX01
emapalumab L04AA39
enasidenib L01XX59
encorafenib L01XE46
Continued

629
ATC/DDD classification WHO Drug Information Vol. 31, No. 4, 2017

Temporary

New ATC 5th level codes (continued)

ATC level name/INN ATC code
enisamium iodide J05AX17
epacadostat L01XX58
eravacycline J01AA13
ertugliflozin A10BK04
fexapotide G04CX04
floxuridine L01BC09
galcanezumab N02CX08
glecaprevir and pibrentasvir J05AP57
ibandronic acid and colecalciferol M05BB09
icotinib L01XE48
imidazolyl ethanamide pentandioic acid J05AX21
indocyanine green V04CX01
ipragliflozin A10BK05
isoniazid, sulfamethoxazole, trimethoprim and pyridoxine J04AM08
kagocel J05AX22
lanadelumab B06AC05
letermovir J05AX18
lorlatinib L01XE44
lusutrombopag B02BX07
medroxyprogesterone and estradiol G03AA17
meropenem and vaborbactam J01DH52
metformin and ertugliflozin A10BD23
naldemedine A06AH05
neratinib L01XE45
norgestimate and ethinylestradiol G03AB09
ozanimod L04AA38
patisiran N07XX12
peramivir J05AH03
riboflavin S01XA26
rifampicin, ethambutol and isoniazid J04AM07
roxadustat B03XA05
sitagliptin and ertugliflozin A10BD24
tebipenem pivoxil J01DH06
telotristat A07XA05
tildrakizumab L04AC17
tilorone J05AX19
tosufloxacin J01MA22
uramustine L01AD08
vaginal ring with progestogen G02BB02
valbenazine N07XX13
valsartan and nebivolol C09DX05

1 Oral formulations indicated for multiple sclerosis.

Parenteral formulations are classified in L01BB04.

630
WHO Drug Information Vol. 31, No. 4, 2017 ATC/DDD classification

Temporary

Change of ATC level name

Previous New ATC code
dinutuximab dinutuximab beta L01XC16

New DDDs
ATC level name/INN DDD unit Adm.R* ATC code
atazanavir and ritonavir 0.3 g1 O J05AR23
baricitinib 4 mg O L04AA37
cariprazine 3 mg O N05AX15
cefroxadine 2.1 g O J01DB11
cefteram 0.4 g O J01DD18
ceftriaxone and beta-lactamase
2 g2 P J01DD63
inhibitor
colistin 9 MU O A07AA10
delafloxacin 0.9 g O J01MA23
delafloxacin 0.6 g P J01MA23
delamanid 0.2 g O J04AK06
desfesoterodine 3.5 mg O G04BD13
droxidopa 1 g O C01CA27
eluxadoline 0.2 g O A07DA06
enisamium iodide 1.5 g O J05AX17
estradiol 1.53 mg TD spray G03CA03
faropenem 0.75 g O J01DI03
follitropin delta 12 mcg P G03GA10
garenoxacin 0.4 g O J01MA19
gemifloxacin 0.32 g O J01MA15
imidazolyl ethanamide pentandioic
90 mg O J05AX21
acid
insulin glargine and lixisenatide 40 U3
P A10AE54
kagocel 60 mg O J05AX22
kanamycin 3 g O A07AA08
lomefloxacin 0.4 g O J01MA07
mepyramine theophyllinacetate 0.6 g O R03DA12
midecamycin 1.2 g O J01FA03
misoprostol 0.2 mg O G02AD06
naldemedine 0.2 mg O A06AH05
nusinersen 0.1 mg P M09AX07
patiromer calcium 16.8 g O V03AE09
pyrimethamine, combinations 75 mg4 P P01BD51
reslizumab 7.1 mg P R03DX08
rimantadine 0.2 g O J05AC02
sarilumab 14.3 mg P L04AC14
secnidazole 2 g O P01AB07
Continued

631
ATC/DDD classification WHO Drug Information Vol. 31, No. 4, 2017

Temporary

New DDDs (continued)

ATC level name/INN DDD unit Adm.R* ATC code
tebipenem pivoxil 0.56 g O J01DH06
thyroid gland preparations 0.1 g O H03AA05
tilorone 0.125 g O J05AX19
tosufloxacin 0.45 g O J01MA22
* Administration Route: O = oral; P = parenteral.
1 refers to atazanavir.
2 refers to ceftriaxone.
3 refers to insulin glargine.
4 refers to pyrimethamine.

Changes of DDDs
ATC level name/INN Previous DDD New DDD ATC code
DDD Unit Adm.R.* DDD Unit Adm.R.*
amoxicillin 1 g O 1.5 g O J01CA04
amoxicillin 1 g P 3 g P J01CA04
amoxicillin and beta-
1 g O 1.5 g O J01CR02
lactamase inhibitor1
ampicillin 2 g P 6 g P J01CA01
cefepime 2 g P 4 g P J01DE01
ciprofloxacin 0.5 g P 0.8 g P J01MA02
colistin 3 MU P 9 MU P J01XB01
meropenem 2 g P 3 g P J01DH02
* Administration Route: O = oral; P = parenteral.
1 New ATC level name valid from 2018.

WHO Collaborating Centre for Drug Statistics Methodology

Oslo, November 2017

632
WHO Drug Information Vol. 31, No. 4, 2017 ATC/DDD classification

ATC/DDD classification (final)

The following ATC codes and DDDs were agreed at the meeting of the WHO
International Working Group for Drug Statistics Methodology in March 2017.
These are considered final and included in the January 2018 version of the ATC/
DDD Index.

New ATC 5th level codes

ATC level name/INN ATC code
andexanet alfa V03AB38
atorvastatin and perindopril C10BX15
cenegermin S01XA24
colecalciferol, combinations A11CC55
cytisine N07BA04
dolutegravir and rilpivirine J05AR21
durvalumab L01XC28
emicizumab B02BX06
emtricitabine, tenofovir alafenamide and bictegravir J05AR20
emtricitabine, tenofovir alafenamide, darunavir and cobicistat J05AR22
erenumab N02CX07
ermekumab L01XC29
evogliptin A10BH07
fimasartan and diuretics C09DA10
formoterol, glycopyrronium bromide and beclometasone R03AL09
guselkumab L04AC16
ivacaftor and tezacaftor R07AX31
lifitegrast S01XA25
metformin and evogliptin A10BD22
nusinersen M09AX07
oxycodone and naltrexone N02AA56
plecanatide A06AX07
polmacoxib M01AH07
ropeginterferon alfa-2b L03AB15
sirukumab L04AC15
sofosbuvir, velpatasvir and voxilaprevir J05AP56
tavaborole D01AE24
vestronidase alfa A16AB18
vilanterol, umeclidinium bromide and fluticasone furoate R03AL08

633
ATC/DDD classification WHO Drug Information Vol. 31, No. 4, 2017

Final

Changes of ATC level names

Previous New ATC code
Adrenergics in combinations with Adrenergics in combinations with R03AL
anticholinergics anticholinergics incl. triple combinations
with corticosteroids1
eptacog alfa coagulation factor VIIa B02BD08
1 Decided at the October 2017 meeting of the WHO International Working Group for Drug Statistics
Methodology. To be implemented in the 2018 version of the ATC/DDD index.

New DDDs
ATC level name/INN DDD unit Adm.R* ATC code
brexpiprazole 3 mg O N05AX16
cyclizine 0.1 g P R06AE03
etelcalcetide 2.1 mg P H05BX04
evogliptin 5 mg O A10BH07
ixekizumab 2.9 mg P L04AC13
levomethadone 15 mg O N07BC05
methotrexate 2.5 mg P L04AX03
obeticholic acid 10 mg O A05AA04
plecanatide 3 mg O A06AX07
tenofovir alafenamide 25 mg O J05AF13
* Administration Route: O = oral; P = parenteral.

Change of DDD
ATC level name/INN Previous DDD New DDD ATC code
DDD Unit Adm.R.* DDD Unit Adm.R.*
glycopyrronium bromide 3 mg P 0.3 mg P A03AB02
* Administration Route: P = parenteral.

WHO Collaborating Centre for Drug Statistics Methodology

Oslo, November 2017

634